{"id":3554,"date":"2022-09-08T14:58:52","date_gmt":"2022-09-08T11:58:52","guid":{"rendered":"https:\/\/info.e-med.co.il\/remsima\/?p=3554"},"modified":"2023-10-25T15:03:21","modified_gmt":"2023-10-25T12:03:21","slug":"efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study","status":"publish","type":"post","link":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/","title":{"rendered":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study"},"content":{"rendered":"<h3 class=\"title\" dir=\"ltr\" style=\"text-align: left;\">Abstract<\/h3>\n<div id=\"eng-abstract\" class=\"abstract-content selected\">\n<p dir=\"ltr\" style=\"text-align: left;\"><strong class=\"sub-title\">Background:\u00a0<\/strong>Intravenous [IV] infliximab is a well-established therapy for inflammatory bowel diseases [IBD] patients. A subcutaneous [SC] formulation of infliximab [CT-P13] has recently been shown to be as effective as IV infliximab after two doses of IV induction in a randomised trial, but there are no data to support elective switching of patients on maintenance IV infliximab therapy.<\/p>\n<p style=\"text-align: right;\"><strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35390141\/\" target=\"_blank\" rel=\"noopener\">\u05dc\u05d4\u05de\u05e9\u05da \u05e7\u05e8\u05d9\u05d0\u05d4<\/a><\/strong><\/p>\n<\/div>\n<p dir=\"ltr\">Smith PJ, Critchley L, Storey D, Gregg B, Stenson J, Kneebone A, Rimmer T, Burke S, Hussain S, Yi Teoh W, Vazeille S, Serna S, Steel A, Derbyshire E, Collins P, Dibb M, Flanagan P, Probert C, Verma AM, Subramanian S. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. J Crohns Colitis. 2022 Sep 8;16(9):1436-1446. doi: 10.1093\/ecco-jcc\/jjac053. PMID: 35390141; PMCID: PMC9455786.<\/p>\n","protected":false},"excerpt":{"rendered":"<p dir=\"ltr\"><strong>Smith et.al.; \u00a0Journal of Crohn's and Colitis, 2022 Sep 8;16(9):1436-1446 \u00a0<\/strong><\/p>\n","protected":false},"author":2,"featured_media":3555,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"footnotes":""},"categories":[28,26,24],"tags":[],"class_list":["post-3554","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-article-en","category-research","category-updates-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Smith et.al.; Journal of Crohn&#039;s and Colitis, 2022 Sep 8;16(9):1436-1446\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"&#039;\u05de\u05e2\u05e8\u05db\u05ea \u05d0\u05d9\u05de\u05d3&#039;\"\/>\n\t<meta name=\"keywords\" content=\"article,\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd,\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"he_IL\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Remsima | \u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de&quot;\u05d2\/\u05de&quot;\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study | Remsima\" \/>\n\t\t<meta property=\"og:description\" content=\"Smith et.al.; Journal of Crohn&#039;s and Colitis, 2022 Sep 8;16(9):1436-1446\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2022-09-08T11:58:52+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2023-10-25T12:03:21+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study | Remsima\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Smith et.al.; Journal of Crohn&#039;s and Colitis, 2022 Sep 8;16(9):1436-1446\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#article\",\"name\":\"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study | Remsima\",\"headline\":\"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study\",\"author\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/files\\\/2023\\\/10\\\/colitus.jpg\",\"width\":674,\"height\":506},\"datePublished\":\"2022-09-08T14:58:52+03:00\",\"dateModified\":\"2023-10-25T15:03:21+03:00\",\"inLanguage\":\"he-IL\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#webpage\"},\"articleSection\":\"Article, \\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd, \\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/#listItem\",\"name\":\"\\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/#listItem\",\"position\":2,\"name\":\"\\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\",\"item\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/#listItem\",\"name\":\"\\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/#listItem\",\"position\":3,\"name\":\"\\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd\",\"item\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#listItem\",\"name\":\"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/updates-news\\\/#listItem\",\"name\":\"\\u05e2\\u05d3\\u05db\\u05d5\\u05e0\\u05d9\\u05dd\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#listItem\",\"position\":4,\"name\":\"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/research\\\/#listItem\",\"name\":\"\\u05de\\u05d7\\u05e7\\u05e8\\u05d9\\u05dd \\u05d5\\u05e4\\u05e8\\u05e1\\u05d5\\u05de\\u05d9\\u05dd\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#organization\",\"name\":\"\\u05e4\\u05d0\\u05d3\\u05d0\\u05d2\\u05d9\\u05e1 \\u05d9\\u05e9\\u05e8\\u05d0\\u05dc \\u05e1\\u05d5\\u05db\\u05e0\\u05d5\\u05d9\\u05d5\\u05ea \\u05d1\\u05e2\\\"\\u05de\",\"description\":\"\\u05e8\\u05de\\u05e1\\u05d9\\u05de\\u05d4 120 \\u05de\\\"\\u05d2\\\/\\u05de\\\"\\u05dc \\u05ea\\u05ea -\\u05e2\\u05d5\\u05e8\\u05d9 \\u05d4\\u05d9\\u05e0\\u05d5 \\u05d4\\u05d0\\u05d9\\u05e0\\u05e4\\u05dc\\u05d9\\u05e7\\u05e1\\u05d9\\u05de\\u05d0\\u05d1 \\u05d4\\u05d9\\u05d7\\u05d9\\u05d3 \\u05db\\u05d9\\u05d5\\u05dd \\u05d4\\u05e0\\u05d9\\u05ea\\u05df \\u05d1\\u05de\\u05ea\\u05df \\u05ea\\u05ea-\\u05e2\\u05d5\\u05e8\\u05d9\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/files\\\/2023\\\/11\\\/remsima_150.jpg\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#organizationLogo\",\"width\":150,\"height\":150},\"image\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/\",\"name\":\"'\\u05de\\u05e2\\u05e8\\u05db\\u05ea \\u05d0\\u05d9\\u05de\\u05d3'\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a33eb712ef50ecea3e80558c3ebca581471b3c91aeab90167c90d04c73f5e3b?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"'\\u05de\\u05e2\\u05e8\\u05db\\u05ea \\u05d0\\u05d9\\u05de\\u05d3'\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#webpage\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/\",\"name\":\"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study | Remsima\",\"description\":\"Smith et.al.; Journal of Crohn's and Colitis, 2022 Sep 8;16(9):1436-1446\",\"inLanguage\":\"he-IL\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/author\\\/naama2shomroni23\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/files\\\/2023\\\/10\\\/colitus.jpg\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#mainImage\",\"width\":674,\"height\":506},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\\\/#mainImage\"},\"datePublished\":\"2022-09-08T14:58:52+03:00\",\"dateModified\":\"2023-10-25T15:03:21+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#website\",\"url\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/\",\"name\":\"Remsima\",\"description\":\"\\u05e8\\u05de\\u05e1\\u05d9\\u05de\\u05d4 120 \\u05de\\\"\\u05d2\\\/\\u05de\\\"\\u05dc \\u05ea\\u05ea -\\u05e2\\u05d5\\u05e8\\u05d9 \\u05d4\\u05d9\\u05e0\\u05d5 \\u05d4\\u05d0\\u05d9\\u05e0\\u05e4\\u05dc\\u05d9\\u05e7\\u05e1\\u05d9\\u05de\\u05d0\\u05d1 \\u05d4\\u05d9\\u05d7\\u05d9\\u05d3 \\u05db\\u05d9\\u05d5\\u05dd \\u05d4\\u05e0\\u05d9\\u05ea\\u05df \\u05d1\\u05de\\u05ea\\u05df \\u05ea\\u05ea-\\u05e2\\u05d5\\u05e8\\u05d9\",\"inLanguage\":\"he-IL\",\"publisher\":{\"@id\":\"https:\\\/\\\/info.e-med.co.il\\\/remsima\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study | Remsima","description":"Smith et.al.; Journal of Crohn's and Colitis, 2022 Sep 8;16(9):1436-1446","canonical_url":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/","robots":"max-image-preview:large","keywords":"article,\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd,\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#article","name":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study | Remsima","headline":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study","author":{"@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author"},"publisher":{"@id":"https:\/\/info.e-med.co.il\/remsima\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/info.e-med.co.il\/remsima\/files\/2023\/10\/colitus.jpg","width":674,"height":506},"datePublished":"2022-09-08T14:58:52+03:00","dateModified":"2023-10-25T15:03:21+03:00","inLanguage":"he-IL","mainEntityOfPage":{"@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#webpage"},"isPartOf":{"@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#webpage"},"articleSection":"Article, \u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd, \u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd"},{"@type":"BreadcrumbList","@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima#listItem","position":1,"name":"Home","item":"https:\/\/info.e-med.co.il\/remsima","nextItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/#listItem","name":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd"}},{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/#listItem","position":2,"name":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd","item":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/","nextItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/research\/#listItem","name":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd"},"previousItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/research\/#listItem","position":3,"name":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd","item":"https:\/\/info.e-med.co.il\/remsima\/research\/","nextItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#listItem","name":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study"},"previousItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/#listItem","name":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd"}},{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#listItem","position":4,"name":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study","previousItem":{"@type":"ListItem","@id":"https:\/\/info.e-med.co.il\/remsima\/research\/#listItem","name":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd"}}]},{"@type":"Organization","@id":"https:\/\/info.e-med.co.il\/remsima\/#organization","name":"\u05e4\u05d0\u05d3\u05d0\u05d2\u05d9\u05e1 \u05d9\u05e9\u05e8\u05d0\u05dc \u05e1\u05d5\u05db\u05e0\u05d5\u05d9\u05d5\u05ea \u05d1\u05e2\"\u05de","description":"\u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de\"\u05d2\/\u05de\"\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9","url":"https:\/\/info.e-med.co.il\/remsima\/","logo":{"@type":"ImageObject","url":"https:\/\/info.e-med.co.il\/remsima\/files\/2023\/11\/remsima_150.jpg","@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#organizationLogo","width":150,"height":150},"image":{"@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author","url":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/","name":"'\u05de\u05e2\u05e8\u05db\u05ea \u05d0\u05d9\u05de\u05d3'","image":{"@type":"ImageObject","@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/4a33eb712ef50ecea3e80558c3ebca581471b3c91aeab90167c90d04c73f5e3b?s=96&d=mm&r=g","width":96,"height":96,"caption":"'\u05de\u05e2\u05e8\u05db\u05ea \u05d0\u05d9\u05de\u05d3'"}},{"@type":"WebPage","@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#webpage","url":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/","name":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study | Remsima","description":"Smith et.al.; Journal of Crohn's and Colitis, 2022 Sep 8;16(9):1436-1446","inLanguage":"he-IL","isPartOf":{"@id":"https:\/\/info.e-med.co.il\/remsima\/#website"},"breadcrumb":{"@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#breadcrumblist"},"author":{"@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author"},"creator":{"@id":"https:\/\/info.e-med.co.il\/remsima\/author\/naama2shomroni23\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/info.e-med.co.il\/remsima\/files\/2023\/10\/colitus.jpg","@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#mainImage","width":674,"height":506},"primaryImageOfPage":{"@id":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/#mainImage"},"datePublished":"2022-09-08T14:58:52+03:00","dateModified":"2023-10-25T15:03:21+03:00"},{"@type":"WebSite","@id":"https:\/\/info.e-med.co.il\/remsima\/#website","url":"https:\/\/info.e-med.co.il\/remsima\/","name":"Remsima","description":"\u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de\"\u05d2\/\u05de\"\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9","inLanguage":"he-IL","publisher":{"@id":"https:\/\/info.e-med.co.il\/remsima\/#organization"}}]},"og:locale":"he_IL","og:site_name":"Remsima | \u05e8\u05de\u05e1\u05d9\u05de\u05d4 120 \u05de&quot;\u05d2\/\u05de&quot;\u05dc \u05ea\u05ea -\u05e2\u05d5\u05e8\u05d9 \u05d4\u05d9\u05e0\u05d5 \u05d4\u05d0\u05d9\u05e0\u05e4\u05dc\u05d9\u05e7\u05e1\u05d9\u05de\u05d0\u05d1 \u05d4\u05d9\u05d7\u05d9\u05d3 \u05db\u05d9\u05d5\u05dd \u05d4\u05e0\u05d9\u05ea\u05df \u05d1\u05de\u05ea\u05df \u05ea\u05ea-\u05e2\u05d5\u05e8\u05d9","og:type":"article","og:title":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study | Remsima","og:description":"Smith et.al.; Journal of Crohn's and Colitis, 2022 Sep 8;16(9):1436-1446","og:url":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/","article:published_time":"2022-09-08T11:58:52+00:00","article:modified_time":"2023-10-25T12:03:21+00:00","twitter:card":"summary","twitter:title":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study | Remsima","twitter:description":"Smith et.al.; Journal of Crohn's and Colitis, 2022 Sep 8;16(9):1436-1446"},"aioseo_meta_data":{"post_id":"3554","title":null,"description":null,"keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_custom_image_width":null,"og_custom_image_height":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema_type":null,"schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"none","tabs":null,"priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"created":"2023-10-25 11:58:49","updated":"2026-05-15 00:39:37","primary_term":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"twitter_image_url":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"Article","isEnabled":true},"graphs":[]},"limit_modified_date":false,"ai":null,"seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/info.e-med.co.il\/remsima\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/info.e-med.co.il\/remsima\/updates-news\/\" title=\"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd\">\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/info.e-med.co.il\/remsima\/research\/\" title=\"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd\">\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tEfficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/info.e-med.co.il\/remsima"},{"label":"\u05e2\u05d3\u05db\u05d5\u05e0\u05d9\u05dd","link":"https:\/\/info.e-med.co.il\/remsima\/updates-news\/"},{"label":"\u05de\u05d7\u05e7\u05e8\u05d9\u05dd \u05d5\u05e4\u05e8\u05e1\u05d5\u05de\u05d9\u05dd","link":"https:\/\/info.e-med.co.il\/remsima\/research\/"},{"label":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study","link":"https:\/\/info.e-med.co.il\/remsima\/efficacy-and-safety-of-elective-switching-from-intravenous-to-subcutaneous-infliximab-ct-p13-a-multicentre-cohort-study\/"}],"_links":{"self":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts\/3554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/comments?post=3554"}],"version-history":[{"count":1,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts\/3554\/revisions"}],"predecessor-version":[{"id":3556,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/posts\/3554\/revisions\/3556"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/media\/3555"}],"wp:attachment":[{"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/media?parent=3554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/categories?post=3554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/info.e-med.co.il\/remsima\/wp-json\/wp\/v2\/tags?post=3554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}